Work

Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis

Year: 2025

Type: review

Abstract: Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Although different risk factors condition the evolution and outcome of CVDs, a limited number of common pathological pathways converge in adverse cardiac remodeling. Among these, cardiac fibrosis has been postulated not only as a mechanism for the onset and development of CVDs but also as a predictor of disease severity. Tools to diagnose subclinical cardiac fibrosis and therapies targeting cardiac fibrosis constitute an essential line of research in CVDs. To date, magnetic resonance imaging (MRI) is a sensitive tool for diagnosing cardiac fibrosis, but sampling errors can occur. Moreover, its availability is limited by the high cost of the equipment. For this reason, nanotechnology offers a promising approach for developing nanosystems directed at molecular targets of cardiac damage, to provide both affordable and readily available diagnostics and the possibility of targeted therapy. This review will showcase major research advances on the role of nanoparticles in cardiac fibrosis. It will discuss the advantages and limitations of nanoparticles, and the standards for advancing them to the clinical phase of treatment and diagnosis of cardiac fibrosis.

Source: International Journal of Nanomedicine

DOI: 10.2147/ijn.s520967

Authors: Yanay Montano-Peguero, Hugo Verdejo, Jaime Riquelme, Marcelo Kogan, Sergio Lavandero

Institutions: Advanced Center for Chronic Diseases, University of Chile, Pontificia Universidad Católica de Chile, The University of Texas Southwestern Medical Center

Language: English

Topic: Cardiac Fibrosis and Remodeling

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,836